Table 1. Potential possibilities to improve the outcomes of MD-DC based therapeutic vaccines.

New immunogens	- autologous vs heterologous immunogens      - mRNA      - Viral vectors      - Dendrimers      - Nanoparticles
Adjuvants.	- ADA      - Anti PD1 and Anti PDL-1 antibodies
Clinical trial design.	- booster doses of immunogen after cART interruption      - prime-boost immunization with viral vectors and DC–based vaccines
in vivo DC targeting immunogens	- to improve the capture and antigen presentation avoiding the cumbersome manipulation of DCs.